H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 133 Citations 69,272 709 World Ranking 898 National Ranking 26

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

His primary scientific interests are in Glioma, Cancer research, Internal medicine, Oncology and Temozolomide. His Glioma research includes themes of Angiogenesis, Paracrine signalling, Bioinformatics, DNA repair and Methyltransferase. His Cancer research research is multidisciplinary, incorporating perspectives in Apoptosis, Programmed cell death and CD8, Immune system.

His studies examine the connections between Internal medicine and genetics, as well as such issues in Anaplastic astrocytoma, with regards to Survival analysis. His work deals with themes such as Clinical trial, Pathology, Personalized medicine and DNA methylation, which intersect with Oncology. His Temozolomide research is multidisciplinary, incorporating elements of Bevacizumab and Chemoradiotherapy.

His most cited work include:

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2349 citations)
  • Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma (1454 citations)
  • Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (1139 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Glioma, Internal medicine, Cancer research, Oncology and Temozolomide. Within one scientific family, Wolfgang Wick focuses on topics pertaining to Magnetic resonance imaging under Glioma, and may sometimes address concerns connected to Nuclear medicine. His Internal medicine research includes elements of Surgery and Glioblastoma.

His work is dedicated to discovering how Cancer research, DNA methylation are connected with Methylation and other disciplines. His Oncology research is multidisciplinary, relying on both Randomized controlled trial and Chemotherapy. His Temozolomide study integrates concerns from other disciplines, such as Phases of clinical research, Clinical endpoint, Hazard ratio, Concomitant and O-6-methylguanine-DNA methyltransferase.

He most often published in these fields:

  • Glioma (42.42%)
  • Internal medicine (36.32%)
  • Cancer research (40.53%)

What were the highlights of his more recent work (between 2019-2021)?

  • Glioma (42.42%)
  • Internal medicine (36.32%)
  • Cancer research (40.53%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Glioma, Internal medicine, Cancer research, Oncology and DNA methylation. A large part of his Glioma studies is devoted to Temozolomide. In general Internal medicine, his work in Clinical trial and Hazard ratio is often linked to Isocitrate dehydrogenase linking many areas of study.

His research investigates the connection between Cancer research and topics such as Brain metastasis that intersect with problems in Cancer cell. His research investigates the link between Oncology and topics such as Proportional hazards model that cross with problems in Bevacizumab. In DNA methylation, Wolfgang Wick works on issues like Pathology, which are connected to Gene panel.

Between 2019 and 2021, his most popular works were:

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions (61 citations)
  • EANO guideline on the diagnosis and treatment of vestibular schwannoma (27 citations)
  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. (24 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Wolfgang Wick mainly investigates Internal medicine, Glioma, DNA methylation, Oncology and Pathology. The various areas that he examines in his Internal medicine study include Gastroenterology and Glioblastoma. His study on Glioma is covered under Cancer research.

The concepts of his Cancer research study are interwoven with issues in Gene expression and Immune system. His Oncology research integrates issues from O-6-methylguanine-DNA methyltransferase, Clinical trial, Cerebrospinal fluid and Spinal muscular atrophy. His Pathology research incorporates elements of Gene panel, Dna methylation profiling and YAP1.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)

2941 Citations

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson.
The New England Journal of Medicine (2014)

1903 Citations

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Dominik Sturm;Hendrik Witt;Hendrik Witt;Volker Hovestadt;Dong Anh Khuong-Quang.
Cancer Cell (2012)

1438 Citations

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott.
Nature (2011)

1305 Citations

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper.
Acta Neuropathologica (2009)

1089 Citations

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin.
Nature Medicine (2002)

952 Citations

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg.
Lancet Oncology (2012)

936 Citations

DNA methylation-based classification of central nervous system tumours

David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
Nature (2018)

860 Citations

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels.
Journal of Clinical Oncology (2009)

859 Citations

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Monika E. Hegi;Lili Liu;James G. Herman;Roger Stupp.
Journal of Clinical Oncology (2008)

849 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Wolfgang Wick

Michael Weller

Michael Weller

University of Zurich

Publications: 296

Andreas von Deimling

Andreas von Deimling

Heidelberg University

Publications: 280

Patrick Y. Wen

Patrick Y. Wen

Harvard University

Publications: 258

Stefan M. Pfister

Stefan M. Pfister

German Cancer Research Center

Publications: 226

David A. Reardon

David A. Reardon

Harvard University

Publications: 159

David Capper

David Capper

Humboldt-Universität zu Berlin

Publications: 155

Timothy F. Cloughesy

Timothy F. Cloughesy

University of California, Los Angeles

Publications: 143

Felix Sahm

Felix Sahm

University Hospital Heidelberg

Publications: 133

Martin J. van den Bent

Martin J. van den Bent

Erasmus University Rotterdam

Publications: 125

Mark R. Gilbert

Mark R. Gilbert

The University of Texas MD Anderson Cancer Center

Publications: 119

Pieter Wesseling

Pieter Wesseling

University of Amsterdam

Publications: 118

David T. W. Jones

David T. W. Jones

German Cancer Research Center

Publications: 117

Matthias Preusser

Matthias Preusser

Medical University of Vienna

Publications: 116

Susan M. Chang

Susan M. Chang

University of California, San Francisco

Publications: 113

Kenneth D. Aldape

Kenneth D. Aldape

Princess Margaret Cancer Centre

Publications: 113

Guido Reifenberger

Guido Reifenberger

Heinrich Heine University Düsseldorf

Publications: 105

Something went wrong. Please try again later.